Eli Lilly and Company announced this week that it has made a lower-cost insulin lispro injection available in pharmacies. The company said that the authorized version carries a list price ($137.35 per vial and $265.20 for a package of 5 pens) that is 50% lower than that of the brand-name Humalog injection.
Eli Lilly and Company announced this week that it has made a lower-cost insulin lispro injection available in pharmacies. The company said that the authorized version carries a list price ($137.35 per vial and $265.20 for a package of 5 pens) that is 50% lower than that of the brand-name Humalog injection.
Because the authorized product is the same formulation as Humalog, it will be substitutable at the pharmacy level. Lilly says that patients should ask their pharmacists whether the branded drug or the authorized version will be cheaper for them under their insurance plans.
The move comes just a month after a House of Representatives subcommittee heard testimony that 1 in 4 patients with diabetes are skipping doses or rationing their insulin due to price, which can lead to severe complications or death. The committee also heard testimony that Humalog cost just $21 per vial in 1996 versus $270 today.
"The current healthcare system isn't working for everyone, causing a growing number of people with chronic conditions to struggle to afford their medicine," said Mike Mason, senior vice president of connected care and insulins for Lilly, in a statement. "But even one person with diabetes who can't afford insulin is too many, which is why we introduced Insulin Lispro Injection. It adds to our suite of solutions that help significantly lower the amount people pay until a more sustainable solution is achieved."
Advocates for patients say that the price of the authorized version of the product is still too high, however; in a statement responding to news that Lilly would launch the cheaper product, Ben Wakana, executive director of Patients For Affordable Drugs, said “Clearly, the insulin cartel is feeling pressure after years of price-gouging a lifesaving drug. But charging nearly $140 for a vial of insulin—a drug that was invented almost a century ago—is still too high. Millions of Americans with Medicare or employer coverage will continue to face Eli Lilly’s exorbitant list price.”
The launch of the reduced-cost version of the drug comes after Lilly issued comments earlier this year regarding the FDA’s proposed approach to the transition of insulins and other products that have historically been regulated as drugs and follow-ons to regulation as biologics and biosimilars.
In its comments to the agency, Lilly voiced its support of the FDA’s proposed approach to the transition, but it also called on the FDA to clarify whether drug product developers can introduce “second versions” of their innovator biologics, calling these potential products “branded biosimilars” or “authorized biologics.”
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.